https://www.bioworld.com/rss en-us A joint Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. patent details new tetrahydrobenzothiazole compounds potentially useful for the treatment of allergic asthma. http://www.bioworld.com/articles/732658 Wed, 15 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732658-jiangsu-hengrui-shanghai-senhui-and-shanghai-shengdi-patent-new-compounds-for-asthma Nuoshen Pharmaceutical (Shanghai) Co. Ltd. has disclosed new NLRP3 inflammasome inhibitors potentially useful for the treatment of neuroinflammation, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s disease. http://www.bioworld.com/articles/732657 Wed, 15 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732657-nuoshen-pharmaceutical-prepares-new-nlrp3-inflammasome-inhibitors Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has prepared and tested new bispecific antibody-drug conjugates (ADCs) consisting of a bispecific antibody or antigen-binding fragments targeting B7 homolog 3 (B7-H3; CD276) and delta-like protein 3 (DLL3) linked to cytotoxic drug; they are described as potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732656 Wed, 15 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732656-biocytogen-pharmaceuticals-discloses-new-anti-dll3-b7h3-adcs Alphina Therapeutics Inc. has identified new nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors potentially useful for the treatment of autoimmune and metabolic diseases, inflammatory disorders and cancer. http://www.bioworld.com/articles/732655 Wed, 15 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732655-nampt-inhibitors-reported-in-alphina-therapeutics-patent Neolaia Inc. has discovered new 6,5-bicyclic compounds acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of cancer, neurodegeneration, fibrosis, renal, inflammatory, autoimmune, metabolic and cardiovascular disease, among others. http://www.bioworld.com/articles/732654 Wed, 15 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732654-neolaia-identifies-new-cd38-inhibitors A joint Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details new S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors potentially useful for the treatment of cancer. S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors potentially useful for the treatment of cancer.]]> http://www.bioworld.com/articles/732640 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732640-hansoh-identifies-new-mat2a-inhibitors Molecule illustration Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed new compounds acting as lipid-lowering agents and gluconeogenesis inhibitors potentially useful for the treatment of metabolic diseases. http://www.bioworld.com/articles/732639 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732639-shanghai-institute-of-materia-medica-patents-new-lipid-lowering-gluconeogenesis-inhibitors Researchers from the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, Nanyang Technological University and the University of Montpellier have patented new Mycobacterium sp. ATP synthase (F0F1 ATPase) inhibitors potentially useful for the treatment of nontuberculous mycobacterial infections. Mycobacterium sp. ATP synthase (F0F1 ATPase) inhibitors potentially useful for the treatment of nontuberculous mycobacterial infections.]]> http://www.bioworld.com/articles/732638 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732638-cnrs-and-collaborators-discover-new-emmycobacterium-em-atpase-inhibitors Wuhan Createrna Science and Technology Co. Ltd. has reported new complement factor D (CFD) inhibitors potentially useful for the treatment of cardiovascular, immunological, eye, genitourinary, renal, respiratory, neurological disorders and hematological diseases. http://www.bioworld.com/articles/732637 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732637-wuhan-createrna-discloses-new-cfd-inhibitors Nutshell Therapeutics Inc. has synthesized new nitrogen-containing heteroaryl compounds acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732636 Tue, 14 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732636-wrn-inhibitors-reported-in-nutshell-therapeutics-patent A federal jury was wrong when it determined that Astrazeneca plc should pay Wyeth, a Pfizer Inc. unit, $107.5 million in damages for infringing two cancer patents, the U.S. Court of Appeals for the Federal Circuit said in a recent precedential decision. http://www.bioworld.com/articles/732584 Mon, 13 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732584-fed-circuit-once-again-instructs-on-enablement-of-rx-claims Novartis AG has reported new drug conjugates comprising drugs targeting fibroblast activation protein α (FAP) covalently linked to a radiolabeled chelating agent through a linker potentially useful for the treatment and/or diagnosis of cancer. http://www.bioworld.com/articles/732578 Mon, 13 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732578-novartis-prepares-new-fap-targeting-radioconjugates Prelude Therapeutics Inc. has identified new tyrosine-protein kinase JAK2 inhibitors potentially useful for the treatment of leukemia, polycythemia vera, myelofibrosis, essential thrombocythemia and graft-vs.-host disease. http://www.bioworld.com/articles/732577 Mon, 13 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732577-jak2-inhibitors-reported-in-prelude-therapeutics-patent Shenzhen Linggene Biotechnology Co. Ltd. has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding agent coupled to a UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase (OGT)-targeting moiety acting as OGT degradation inducers. N-acetylglucosamine-peptide N-acetylglucosaminyltransferase (OGT)-targeting moiety acting as OGT degradation inducers.]]> http://www.bioworld.com/articles/732576 Mon, 13 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732576-shenzhen-linggene-biotechnology-discloses-new-ogt-degradation-inducers Vastpro (Shanghai) Pharmaceutical Technology Development Co. Ltd. has patented new voltage-gated sodium channel blockers potentially useful for the treatment of pain. http://www.bioworld.com/articles/732575 Mon, 13 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732575-vastpro-pharmaceutical-discovers-new-voltage-gated-sodium-channel-blockers Guangzhou Respiratory Medicine Engineering Technology Co. Ltd. has disclosed new cathepsin C (dipeptidyl peptidase I) and neutrophil elastase (ELANE; leukocyte elastase) inhibitors potentially useful for the treatment of asthma, diabetes, psoriasis, nasal polyps, cystic fibrosis and more. http://www.bioworld.com/articles/732574 Mon, 13 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732574-guangzhou-respiratory-medicine-patents-new-cathepsin-c-neutrophil-elastase-inhibitors Suzhou Puhe Biopharma Co. Ltd. has patented new GTPase KRAS mutant inhibitors potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732559 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732559-suzhou-puhe-biopharma-discovers-new-kras-mutant-inhibitors Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of neurodegeneration and inflammatory disorders. http://www.bioworld.com/articles/732558 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732558-nrf2-activators-reported-in-vailima-peninsula-patent Shanghai Peptidstar Therapeutics Ltd. has divulged new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of psoriasis, arthritis and inflammatory bowel disease. http://www.bioworld.com/articles/732557 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732557-shanghai-peptidstar-therapeutics-synthesizes-new-il-23r-antagonists K2 Medicines (Nanjing) Co. Ltd. has disclosed new epidermal growth factor receptor (EGFR; ERBB1; HER1) mutant inhibitors potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732556 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732556-k2-medicines-patents-egfr-mutant-inhibitors Anew Therapeutics Pte Ltd. has discovered new interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors reported be useful for the treatment of Crohn’s disease, type 1 diabetes, dry eye and more. http://www.bioworld.com/articles/732555 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732555-anew-therapeutics-identifies-new-il-17a-il-17ra-interaction-inhibitors Apolin Bio Ltd. and Shanghai Viva Dancheng Entrepreneurship Incubator Management Ltd. have detailed polycyclic compounds acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors that are potentially useful for the treatment of cardiovascular disorders. http://www.bioworld.com/articles/732513 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732513-apolin-bio-and-viva-biotech-present-new-apoa-apob-interaction-inhibitors Nuvalent Inc. has described RAC-α serine/threonine-protein kinase (AKT1; PKBα) E17K mutant inhibitors reported to be useful for the treatment of cancer. http://www.bioworld.com/articles/732512 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732512-nuvalent-discloses-new-akt1-inhibitors U&S Bio Co. Ltd. has divulged H+/K+-ATPase inhibitors with improved stability found to be potentially useful for the treatment of gastrointestinal disorders, cancer, Helicobacter pylori infection, sialorrhea, asthma and airways obstruction, among others. Helicobacter pylori infection, sialorrhea, asthma and airways obstruction, among others.]]> http://www.bioworld.com/articles/732511 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732511-u-and-s-bio-identifies-new-h-k-atpase-inhibitors Prelude Therapeutics Inc. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase (CRBN)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety that are potentially useful for the treatment of cancer. http://www.bioworld.com/articles/732510 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732510-prelude-therapeutics-patents-new-kat6a-targeting-protacs Promomed Rus LLC has identified Janus kinase (JAK) inhibitors reported to be useful for the treatment of alopecia, atopic dermatitis, juvenile arthritis, rheumatoid arthritis, systemic lupus erythematosus and psoriatic arthritis. http://www.bioworld.com/articles/732509 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732509-promomed-rus-discovers-new-jak-inhibitors A Beijing Mabworks Biotech Co. Ltd. patent describes new antibody-drug conjugates (ADCs) comprising antigen-binding fragments or antibodies targeting delta-like protein 3 (DLL3) linked to a cytotoxic drug potentially useful for the treatment of small-cell lung cancer (SCLC). http://www.bioworld.com/articles/732495 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732495-beijing-mabworks-biotech-discloses-new-dll3-targeting-adcs Beijing Jingwei-Yankang Biomedical Co. Ltd. has reported new phenyl-substituted heterocyclic compounds acting as retinol-binding protein 4 (RBP4) inhibitors with potential in the treatment of age-related macular degeneration (AMD). http://www.bioworld.com/articles/732494 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732494-beijing-jingwei-yankang-biomedical-divulges-new-rbp4-inhibitors KU Leuven and Universität Zürich have discovered new tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors potentially useful for the treatment of cancer and metabolic diseases. http://www.bioworld.com/articles/732493 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732493-ku-leuven-and-universitat-zurich-describe-new-ptpn1-ptpn2-inhibitors Pikavation Therapeutics Inc. has patented new phosphatidylinositol 3-kinase α (PI3Kα) inhibitors potentially useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum. http://www.bioworld.com/articles/732492 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732492-pikavation-therapeutics-identifies-new-pi3k-inhibitors